Anna F. Farago
Amgen Inc.
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Cancer Treatment and Pharmacology
Solid evidence · 2 supporting papers · latest 2026
Statistical Methods in Clinical Trials
Solid evidence · 1 supporting paper · latest 2026
CAR-T cell therapy research
Solid evidence · 1 supporting paper · latest 2026
Monoclonal and Polyclonal Antibodies Research
Solid evidence · 1 supporting paper · latest 2026
Immunotherapy and Immune Responses
Supporting evidence · 1 supporting paper · latest 2026
Cancer Genomics and Diagnostics
Supporting evidence · 1 supporting paper · latest 2026
Publications (3)
Abstract IA01: Moving phase 1 trials to first-line metastatic disease: Challenges and Opportunities
2025DOI
Unlocking the potential of T cell engagers in solid tumors
2026DOIPMID 41997137
Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs
2026DOIPMID 42236300
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Amgen Inc.
Source: OpenAlex · retrieved 2026-09-29